Related Experiment Videos
Calciphylaxis: Beyond CKD-MBD
María Fernández1, Enrique Morales1, Eduardo Gutierrez1
1Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, España.
Insights
Calcific uraemic arteriolopathy (CUA) is a rare vascular disorder with high mortality, particularly in kidney transplant patients. Steroid use and chronic renal failure are key risk factors, necessitating further research into standardized treatments.
Area of Science:
- Nephrology
- Vascular Medicine
- Dermatology
Background:
- Calcific uraemic arteriolopathy (CUA), or calciphylaxis, is a rare, severe vascular disease predominantly affecting patients with chronic kidney disease.
- Understanding CUA's risk factors and clinical outcomes is crucial due to its high mortality rate.
Purpose of the Study:
- To investigate the risk factors associated with the development of CUA.
- To analyze the clinical course and treatment outcomes of patients diagnosed with CUA.
Main Methods:
- A retrospective analysis of 28 patients diagnosed with CUA between December 1999 and December 2015.
- Evaluation of patient demographics, renal function status, treatment modalities, and survival rates.
Main Results:
- Steroid use was a significant risk factor in renal transplant patients (100%).
- Skin lesions resolved in 60.7% of patients, particularly with multitargeted therapy.
- 12-month survival rates varied: 29% for transplant, 57% for hemodialysis, and 100% for normal renal function patients.
- Chronic renal failure and hypoalbuminemia were identified as major mortality risk factors.
Conclusions:
- CUA, despite its low incidence, carries a high mortality rate, demanding increased attention in kidney transplant recipients and non-renal forms.
- Oral anticoagulants and steroids are implicated as primary risk factors.
- Establishing a patient registry and defining standard therapies are essential for managing this challenging condition.
Introduction:
Calcific uraemic arteriolopathy (CUA), also called calciphylaxis, is a rare but potentially fatal vascular disorder that almost exclusively affects patients with chronic renal failure. The objective of this study was to analyse various risk factors for developing CUA and its subsequent clinical course according to the treatment received.
Materials And Methods:
A retrospective study that included patients diagnosed with CUA from December 1999 to December 2015. Various risk factors, clinical course and treatment options were analysed.
Results:
A total of 28 patients (53.6% females) with a mean age of 67.2±11.8 (38-88) years were included. At the time of diagnosis, 53.6% were on haemodialysis, 25% were kidney transplant patients and 21.4% had normal renal function. The use of steroids (100%, P=.001) was the main risk factor in renal transplant patients. Skin lesions resolved in 60.7% (especially in those receiving multitargeted therapy). Patient survival at 12 months was 29% in transplant patients, 57% in haemodialysis patients and 100% in normal renal function patients (log-rank 6.88, P=.032). Chronic renal failure (P=.03) and hypoalbuminaemia (P=.02) were the main risk factor for CUA mortality.
Conclusions:
Although the incidence of CUA remains low, CUA mortality is very high, Special attention to its occurrence in kidney transplant patients and «non-renal» CUA forms is required. Oral anticoagulants and steroids appear to be the main risk factors, CUA is a challenge; a registry of patients and determining standard therapy are required.